Inventor
DUBRIDGE ROBERT B
US37 patents
⚠️ This page may combine multiple inventors who share the name “DUBRIDGE ROBERT B”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
HARPOON THERAPEUTICS INC
11 patentsUS10100106B2Oct 16, 2018
Single domain serum albumin binding protein
HARPOON THERAPEUTICS INC27 citations94
US9920115B2Mar 20, 2018
Single domain serum albumin binding protein
HARPOON THERAPEUTICS INC31 citations94
US10066016B2Sep 4, 2018
Single chain variable fragment CD3 binding proteins
HARPOON THERAPEUTICS INC34 citations93
US10844134B2Nov 24, 2020
PSMA targeting trispecific proteins and methods of use
HARPOON THERAPEUTICS INC12 citations85
US10730954B2Aug 4, 2020
MSLN targeting trispecific proteins and methods of use
HARPOON THERAPEUTICS INC14 citations85
US10543271B2Jan 28, 2020
Mesothelin binding proteins
HARPOON THERAPEUTICS INC13 citations85
US10544221B2Jan 28, 2020
Single chain variable fragment CD3 binding proteins
HARPOON THERAPEUTICS INC14 citations85
US11453716B2Sep 27, 2022
Single domain serum albumin binding protein
HARPOON THERAPEUTICS INC1 citations73
US12528859B2Jan 20, 2026
Single domain serum albumin binding protein
HARPOON THERAPEUTICS INC0 citations62
US11607453B2Mar 21, 2023
Mesothelin binding proteins
HARPOON THERAPEUTICS INC0 citations62
US11623958B2Apr 11, 2023
Single chain variable fragment CD3 binding proteins
HARPOON THERAPEUTICS INC1 citations61
LYNX THERAPEUTICS INC
6 patentsUS5714330AFeb 3, 1998
DNA sequencing by stepwise ligation and cleavage
LYNX THERAPEUTICS INC446 citations99
US6265163B1Jul 24, 2001
Solid phase selection of differentially expressed genes
LYNX THERAPEUTICS INC104 citations98
US6013445AJan 11, 2000
Massively parallel signature sequencing by ligation of encoded adaptors
LYNX THERAPEUTICS INC617 citations98
US5888737AMar 30, 1999
Adaptor-based sequence analysis
LYNX THERAPEUTICS INC214 citations98
US6175002B1Jan 16, 2001
Adaptor-based sequence analysis
LYNX THERAPEUTICS INC94 citations97
US6511802B1Jan 28, 2003
Solid phase selection of differentially expressed genes
LYNX THERAPEUTICS INC30 citations92
TAKEDA PHARMACEUTICALS CO
6 patentsUS11406710B2Aug 9, 2022
Constrained conditionally activated binding proteins
TAKEDA PHARMACEUTICALS CO8 citations83
US11744892B2Sep 5, 2023
Constrained conditionally activated binding proteins
TAKEDA PHARMACEUTICALS CO2 citations70
US11744893B2Sep 5, 2023
Constrained conditionally activated binding proteins
TAKEDA PHARMACEUTICALS CO2 citations70
US11685780B2Jun 27, 2023
Single domain antigen binding domains that bind human Trop2
TAKEDA PHARMACEUTICALS CO2 citations70
US12128102B2Oct 29, 2024
Constrained conditionally activated binding proteins
TAKEDA PHARMACEUTICALS CO1 citations61
US12478673B2Nov 25, 2025
Constrained conditionally activated binding proteins
TAKEDA PHARMACEUTICALS CO0 citations60
CELL GENESYS INC
3 patentsUS6514752B1Feb 4, 2003
Homologous recombination for universal donor cells and chimeric mammalian hosts
CELL GENESYS INC60 citations94
US6139835AOct 31, 2000
Homologous recombination for allogeneic donor cells
CELL GENESYS INC54 citations94
US5670148ASep 23, 1997
Combined cellular and immunosuppressive therapies
CELL GENESYS INC42 citations90